The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT03879863 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

422

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%) QID
DRUG: Vehicle Ophthalmic Solution QID
DRUG: Reproxalap Ophthalmic Solution (0.25%) QID to BID
DRUG: Vehicle Ophthalmic Solution QID to BID

Sponsor

Aldeyra Therapeutics, Inc.